Please upgrade your browser.
From NPR's Morning Edition: A researcher has found a potential new therapy for patients with kidney cancer, which historically hasn't responded well to treatments such as radiation and chemotherapy.
(PressZoom) - STANFORD, Calif. Kidney cancer patients generally have one option for beating their disease: surgery to remove the organ. But that could change, thanks to a new molecule found by Stanford University School of Medicine researchers that kills kidney cancer cells. Ideally, the researchers said, a drug created from this molecule would help fight the life-threatening disease while leaving patients kidneys intact. Source: PressZoom
ImmunoGen, Inc. IMGN today announced the start of patient dosing in a Phase I clinical trial evaluating the Companys IMGN388 targeted anticancer compound for the treatment of solid tumors.
This study is one of the first to identify a trait unique to a certain form of cancer -- in this case, kidney cancer's deficient VHL gene -- and exploit it to defeat the disease,
The team, led by Prof David Cheresh of the University of California, San Diego, showed this way to ensure toxic chemotherapy is delivered precisely where it is needed had "a profound impact on metastasis in pancreatic and kidney cancer in mice."
A cancer patient sent home to die by the National Health Service has seen his health improve after he cashed in his pension and used funds raised by friends to pay privately for an expensive drug.
A team of researchers led by Christopher Wood of the Anderson Cancer Center in Houston, Texas gave the vaccine, called vitespen or Oncophage, to 409 patients whose cancerous tumours had been removed.
A judge has asked an NHS panel to reconsider its decision to refuse a powerful cancer drug to a woman who is the sole carer of her seriously ill husband.
The new vaccine vitespen didn't increase recurrence-free survival among kidney cancer patients who'd had surgery, say U.S. researchers.
Nearly 3,000 people came to Eisenhower for the June 23 dinner and auction to show their support for the Shelby Township 17-year-old who is currently undergoing treatment for an aggressive form of renal cell carcinoma.
|Powered by NeonCRM|